secwatch.observer — SEC 8-K summary
======================================

Issuer:     Roivant Sciences Ltd. (ROIV)
CIK:        0001635088
Form:       8-K
Filed at:   2023-11-28T23:59:59+00:00
Accession:  0001140361-23-054826
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Roivant: IMVT-1402 600 mg Phase 1 data shows best-in-class potential; 74% IgG reduction
--------------------------------------------------------------------------------

- Four weekly SC doses of 600 mg IMVT-1402 reduced total IgG by mean 74%, similar to batoclimab's 76% reduction.
- Serum albumin and LDL-C at Day 29 showed no significant change from baseline (p>0.05), indicating placebo-like safety.
- Steady-state IgG reduction expected to reach ~80% with continued weekly dosing, matching batoclimab's timing of 6-8 weeks.
- Treatment was well tolerated with only mild or moderate adverse events observed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1635088/000114036123054826/0001140361-23-054826-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1635088/000114036123054826/ef20015486_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-23-054826

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer